• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present prodrugs and their pharmaceutically suitable salts have functional groups sensitive to weak acids and have the ability to slowly hydrolyze to the original active medicament under physiological conditions. The prodrug preferably has the formula X-Y, wherein Y is part of the medicament having at least one functional group selected from free amino, carboxyl, hydroxyl and / or mercapto groups; And X is one radical selected from radicals of the formulas (i) to (iv): In the above formula, R 1 and R 2 are the same or different from each other, and hydrogen, alkyl, alkoxy, alkoxyalkyl, aryl, alkaryl, aralkyl, halogen, nitro, sulfo, amino, ammonium, carboxyl, PO 3 H 2 Or OPO 3 H 2 ; R 3 and R 4 are the same as or different from each other, and are each hydrogen, alkyl or aryl; And A is OCO- when the radical is bonded to the carboxyl or mercapto group of Y, or to the amino or hydroxyl group of Y. Examples of such prodrugs are Y as part of insulin, human or bovine growth hormone, antibiotics, propanolol and the like.
    公开号:KR20000029806A
    申请号:KR1019997000941
    申请日:1997-08-05
    公开日:2000-05-25
    发明作者:마티트야후 프리드킨；요람 셰흐터；에이탄 게르쇼노브
    申请人:폴리나 벤-아미;야코브 코헨；예다 리서치 앤드 디벨럽먼트 캄파니 리미티드；
    IPC主号:
    专利说明:

    LONG-ACTING DRUGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM}
    Human therapeutic and veterinary therapeutic drugs can be distinguished according to several criteria. For example, protein-peptide and non-peptidyl molecules composed of amino acid structural units may be classified, or the method may be different from oral absorption medicine according to the criteria for the medicine to reach the blood flow regardless of the structure, For example, infusion, intranasal or topical medications.
    Generally, oral absorptive compounds are small in molecular weight, relatively stable, lipophilic (oily) and non-peptidyl. Practically all peptidic and protein medications cannot be distinguished according to the above criteria because of their hydrophilic (non-lipophilic), polarity and metabolic instability and should always be administered by input. Moreover, the medicament is usually a short-lived molecule, since it is rapidly destroyed by various mechanisms in the body, in particular by proteolysis.
    Non-peptide medications are very sufficiently hydrophobic and can reach blood flow through the gastrointestinal passage. Because of their relative chemical stability, non-peptidic medicaments are usually organ-surviving molecules.
    Protein and peptide medications have important and diverse clinical applications, such as insulin in the treatment of diabetes, gonadotropin-releasing hormone (GnRH) analogs used in the treatment of prostate cancer, bone-related disorders. There is calcitonin in. The potential of such molecules is vast, but only partially studied. This is due to the short-lived viability of the molecule and the inconvenience of the method of administration. Non-peptide medications, such as antibiotics, are relatively long-lived but require multiple administrations per day over a week or longer to maintain the desired continuous circulation.
    Oral absorption of medicine is a goal of interest in the treatment of human diseases, particularly for long-term therapeutic treatment. Structural changes in medicine result in increased oral and topical absorption, biostability and ultimately bioavailability. Most approaches modify the medicine, but preserve its natural structure, the life structure. The natural structure is a prerequisite for medicinal efficacy as the place of action of the medicament is specifically recognized. In many cases, however, the natural structure is recognized by the 'clearing machinery system' and destroyed or metabolized and eventually its processing is accelerated. Thus, stabilization of bioactive structures is often studied with enhancement of metabolic stability. Methods such as inclusion, reducing solubility and chemical modification are used to achieve the above goals.
    Many drugs in circulation or in the future, including antibiotics, antiviral agents, antihypertensives, anti-inflammatory agents, analgesics, anti-cholesterol agents, anticarcinogens, antidiabetics, growth-promoters and other drugs, are available if all peptide and non-peptide Even if the sex medication is not applicable, it is highly desirable to extend the half-life. It is particularly desirable for prodrugs associated with natural medicines that are toxic above a certain threshold concentration.
    It is therefore an object of the present invention to provide novel prodrugs which are very sensitive to weak basic conditions and convert from inactive form to active form under physiological conditions in the body.
    Another object of the invention is derived from a medicament with free amino, carboxyl, hydroxyl and / or mercapto groups, which are essentially biologically inactive but are slowly converted to the original active medicament naturally after administration. To provide a prodrug.
    It is another object of the present invention to provide prodrugs that exhibit improved metabolic stability and increased bioavailability.
    It is a further object of the present invention to provide prodrugs which may alternatively be administered, such as oral or transdermal, and penetrate physiological barriers such as the blood-brain barrier.
    It is another object of the present invention to provide a prodrug that can locate a particular medicament on a site of damage in the body.
    Accordingly, the present invention relates to a functional group wherein one or two or more groups of medicaments selected from the group consisting of free amino, carboxyl, hydroxyl and / or mercapto groups are sensitive to base and are removed under weak base conditions such as physiological conditions. A novel prodrug characterized in that it is substituted.
    The new concept of the present invention for sustained-release drugs involves the induction of novel, generally more hydrophobic drug derivatives. In this approach, it is desirable that the cognition of the medicament by its natural form, biological efficacy and destruction system is lost rather than maintained. On the other hand, the advantage of the method is that the modified derivative is naturally hydrolyzed slowly under in vivo conditions to form a naturally active medicament.
    In an embodiment of the invention, the prodrug is represented by the formula:
    X-Y
    In the above formula,
    Y is part of the medicament with at least one functional group selected from free amino, carboxyl, hydroxyl and / or mercapto groups; And
    X is one radical selected from radicals of the formulas (i) to (iv):
    In the above formula, R 1 and R 2 are the same or different from each other, and hydrogen, alkyl, alkoxy, alkoxyalkyl, aryl, alkaryl, aralkyl, halogen, nitro, sulfo, amino, ammonium, carboxyl, PO 3 H 2 Or OPO 3 H 2 ; R 3 and R 4 are the same as or different from each other, and are each hydrogen, alkyl or aryl; And A is OCO- when the radical is bonded to the carboxyl or mercapto group of Y, or to the amino or hydroxyl group of Y.
    In the present invention, Y is a part of a medicament for human and veterinary use having at least one functional group selected from free amino, carboxyl, hydroxyl and / or mercapto groups, wherein the medicament is as follows. It is not limited to this:
    Antidiabetic agents such as insulin; Growth promoters such as human growth hormone and calcined hormone; Aminoglycosides such as gentamicin, neomycin and streptomycin, beta-lactams such as penicillins such as amoxicillin, ampicillin, piperacillin and cephalosporins (e.g., cephaclo, cephminox and cephalexin), carbomycin and erythro Macrolides such as mycin and polypeptide antibiotics such as bacitracin, gramicidine and polymyxin; Synthetic antibacterial agents such as trimethoprim, pyromide acid and sulfamethazine; Analgesics and anti-inflammatory agents such as acetaminophen, aspirin, ibufenac, indomethacin; Anti-allergic and anti-asthmatic agents, such as amlexoxox and chromoline; Anti-cholesterol agents such as crofibric acid, oxyniaxic acid, and tripalanol; Β-adrenergic blockers and antihypertensive agents such as bupranolol, captopril, indenolol, propranolol and 4-aminobutanoic acid; Anti-tumor agents such as daunorubicin, azacytidine, 6-mercaptopurine, interferon, interleukin-2, methotrexate, taxol and vinblastine; Antiviral agents such as acyclovir, gancyclovir, amantadine, interferon, AZT and ribavirin. In the present invention, the medicament also includes pheromone.
    As used herein, "alkyl", "alkoxy", "alkoxyalkyl", "aryl", "alkaryl" and "aralkyl" as used in the definitions of R 1 , R 2 , R 3 and R 4 are carbon atoms 1-8, It is preferably used to represent alkyl radicals of 1-4, for example methyl, ethyl, propyl, isopropyl and butyl and aryl radicals of 6-10 carbon atoms, for example phenyl, naphthyl. "Halogen" includes bromo, fluoro, chloro and urethra.
    In a preferred embodiment of the invention, the functional group is radical (i), wherein R 1 , R 2 , R 3 and R 4 are hydrogen and A is OCO-, ie known 9-fluorenylmethoxycarbonyl ( Fmoc) radical, which is widely used for the temporary reversible protection of amino groups in peptide synthesis (LA Carpino, Acc. Chem. Res. (1987) 20, 401-407). Fmoc groups are particularly suitable for peptide synthesis because they are easy to manipulate on introduction and removal, have good stability, which is a requirement for peptide synthesis, and are easy to purify. Moreover, the 9-fluorenylmethyl (Fm) groups associated therewith are useful for reversible masking of the carboxyl groups of amino acids, for example. The product, 9-fluorenylmethyl ester (Fm-ester), forms a free carboxyl functional group by β-removal reaction path following weak base treatment, and thus can be used in a similar manner for reversible masking of carboxyl groups in medicine. Fmoc-groups also have similar uses for the reversible protection of hydroxyl groups of tyrosine, serine and threonine.
    Halogenated Fmoc radicals (i) wherein at least one of R 1 and R 2 is halogen in the 2 or 7 position, preferably chlorine or bromine; 2-chloro-1-indenylmethoxycarbonyl (CLIMOC) radical (ii); 1-benzo [f] indenylmethoxycarbonyl urethane (BIMOC) radical (VII); Urethane sulfone radicals (i) and radicals in which A corresponding to (i) to (i) are covalent bonds, like Fmoc and Fm, can be used for the substitution of free amino, carboxyl, hydroxyl and mercapto groups in medicine. This can provide a wide range of sensitivity to the removal of the functional group under basic such as physiological conditions. In fact, the radicals of (i) to (iii) belong to the general group of compounds which are hydrolyzed at neutral or weak base pH and weak conditions, for example for use in the temporary reversible protection of α- and ε-amino groups in peptide synthesis. And may be removed from the amino group by β-removal reaction under weakly basic conditions.
    In the present invention, the radicals of (i) to (iii) are preferably Fmoc covalently bonded to the amino and / or hydroxyl moiety or Fm covalently bonded to the carboxyl and / or mercapto moiety, That is, hydrolyzed (via β-removal) at pH 7.4 and 37 ° C. and returned to the free amino, hydrocy, mercapto or carboxyl functionality.
    The prodrugs of the present invention are prepared by the reaction of a medicament with a suitable reagent comprising the radicals of (i) to (iii) above. Several derivatives of 9-fluorenylmethyl (Fm) can be used, for example 9-fluorenylmethyl-N-hydroxysuccinimide (Fmoc-Osu) which is very specific for amino groups; 9-fluorenylmethoxycarbonylcarbonyl chloride (Fmoc-Cl) which reacts covalently with amino and hydroxyl radicals; 9-fluorenylmethylfluorene (Fm-Cl) that reacts with mercapto radicals to form S-Fm derivatives (Bodanszky and Bednar, 1982); And 9-fluorenylmethanol (Fm-OH) which reacts and esterifies with carboxyl groups.
    Functional groups that are sensitive to basic conditions and are removed from amino, carboxyl, hydroxyl or mercapto groups by a different pathway than β-removal can also be used, but this requires excessive manipulation and is not suitable for the protection of medicine. On the other hand, trifluoroacetyl group (TFA), which has similar ease as Fmoc in its removal from amino group, is strongly toxic and TFA-derived medicines are not suitable for therapeutic use. In contrast, Fmoc-amino acids, such as Fmoc-leucine, showed low toxicity in experimental animal models (Burch et al., 1991).
    The invention also relates to a pharmaceutical composition comprising a prodrug according to the invention and a pharmaceutically suitable carrier.
    The present invention relates to a novel long-acting prodrug capable of chemical modification from inactive form to bioactive form in the body and having a weak basic sensitive functional group, more particularly fluorenylmethoxycarbonyl (Fmoc) And fluorenylmethyl (Fm) -substituted prodrugs and pharmaceutical compositions comprising the same.
    1 shows Lys B29- N- (Fmoc) 1 -insulin (closed rectangle), Phe B1 , Lys by cell-free biological assay (phosphorylation of [Glu 4 Tyr] by concentrate of insulin receptor tyrosine kinase) Activity over time of B29- N- (Fmoc) 2 -insulin (open square) and Gly A1 , Phe B1 , Lys B29 -N- (Fmoc) 3 -insulin (forms with all amino groups substituted, open circles) (pH 7.4, 37 ° C.),
    2 is a graph showing the effect on blood glucose levels of normal rats following monotraperitoneal administration of (Fmoc) 2 -insulin (3 mg / rat in 2 ml of 10% DMSO) and NPH-insulin (3 mg / rat).
    FIG. 3 is a graph showing the effect on blood glucose levels of normal rats following the intraperitoneal administration of (Sulfmoc) 2 -insulin and natural insulin (both 3 mg / rat in 1 ml water).
    4 is a graph showing degradation by a mixture of trypsin and chymotrypsin of insulin (open square) and Gly A1 , Phe B1 , Lys B29 -N- (Fmoc) 3 -insulin (closed rhombus),
    FIG. 5 is a graph showing blood glucose levels of streptozotocin (STZ) -treated diabetic rats following administration of Gly A1 , Phe B1 , Lys B29- N- (Fmoc) 3 -insulin (closed circle) and natural insulin (open square).
    6 is a graph showing hypoglycemia of STZ-treated hyperglycemic rats following administration of Phe B1 , Lys B29 -N- (Fmoc) 2 -insulin,
    7 is a graph showing β-adrenergic antagonism by the production of active propranolol following incubation of N-Fmoc-propranolol.
    The present invention relates to prodrugs invented according to new concepts for developing more improved routes of drug administration and thus improving drug stability and bioactivity. According to the new approach of the present invention, it is desirable that the natural structure, biological efficacy and destination-recognition ability of the medicine is lost rather than preserved, but after application the modified medicine is naturally slow to the original active molecule in vivo. Go back.
    According to the new concept of the present invention, many current medicaments can be modified with inactive prodrugs, which prolong their survival by avoiding common and receptor-mediated degradation mechanisms in the organism. The prodrugs of the present invention have been developed to uniformly and naturally regenerate into the original medicament under in vivo physiological conditions. Various chemical methods useful for the production of the prodrugs of the present invention can speed up or slow down the reactivation as needed. Thus, prodrugs can be manufactured to have physical properties such as reduced solubility, thereby reducing the rate of absorption. Moreover, changes in the hydrophobicity index of prodrugs along with natural reactivation characteristics in the blood circulation system can convert oral nonabsorbable medications into gastrointestinal administration prodrugs.
    Prodrugs of the invention include modified insect pheromones, as well as modified medicines for humans and animals.
    In one aspect of the invention, the prodrug is insulin. Currently, insulin is used as a therapeutic agent for increased risk of complications due to abnormal metabolism of blood vessels, lipids, carbohydrates, and proteins, mainly characterized by diabetes, hyperglycemia. Most patients can be clinically classified as either insulin-dependent (IDDM, type I) or insulin-independent (NIDDM, type II) diabetes. In Western society, about 90% of diabetics are type II and the rest are type I. In the United States, about 70% of Type II patients have obesity, which is a factor that can lead to insulin resistance. In type I diabetes, there is a high and selective damage of pancreatic β-cells and a hypoinsulinemia. On the other hand, in type II diabetic patients, no excessive damage of β-cells was detected from Langerhans island, and plasma concentrations of insulin were normal or high for 24 hours due to peripheral resistance to hormone action. Nevertheless, type II diabetics are relatively deficient in insulin, which means that normal pancreatic β-cells should secrete more insulin than normal for hyperglycemia, thus reducing the general resistance to insulin. Helps maintain glyceria
    All forms of diabetes are due to a decrease in the amount of insulin circulating (insulin deficiency) or a decrease in the responsiveness of peripheral tissues to insulin (insulin resistance), which is the opposite of the action of insulin (glucagon, growth hormone, cortisol and Catecholamine). Abnormalities of these hormones cause changes in carbohydrate, lipid, ketone and amino acid metabolism, and at the center of these symptoms is hyperglycemia.
    In plasma, the half-life of insulin is about 5-6 minutes. The breakdown of insulin occurs mainly in the liver and somewhat in the kidneys and muscles. About 50% of the insulin reached in the liver is destroyed in the portal vein and does not reach the normal circulation. Insulin is filtered out of the glomeruli of the kidney and reabsorbed and destroyed by the renal tract.
    Insulin protein breakdown in the liver is mainly due to receptor involvement mechanisms. The complex formed after insulin binds to the receptor enters the cell in the form of small vesicles called endosomes, where destruction begins. Insulin is also transported to lysosomes and destroyed. In hepatocytes, about 50% of insulin entering the cell is destroyed.
    Insulin is very important in the treatment of diabetic ketoacidosis, in the treatment of hyperglycemic non-ketonic coma and type I and II diabetes patients. Subcutaneous administration of insulin is the main treatment method for all Type I and most Type II patients that are not properly controlled by food and / or hypoglycemic agents. In all cases the aim is to normalize blood sugar in all cases of unbalanced metabolism caused by hypoinsulinemia and hyperglycemia.
    Long-term treatment following the subcutaneous administration of insulin is not the same as rapidly increasing or decreasing in response to nutrient intake, and is a peripheral, rather than action on the liver, but with significant success.
    Insulin preparations used for subcutaneous administration are traditionally classified as short-term, medium-term or long-acting insulin, depending on the duration of action, and also by their source. Human insulin is now widely applied, and theoretically human insulin and 1-3 amino acids are less antigenic than other pigs and cattle. However, when highly purified, all three types of insulin have a low degree of stimulating an immune response. At neutral pH the formulation is generally stable and can be stored for a long time at room temperature. For traditional therapeutic purposes, the dosage and concentration of insulin are expressed in units (U) depending on the amount needed to induce normal blood glucose in fast rabbit. Homogeneous preparations of insulin comprise about 25 U / mg. Commercialized insulin preparations are supplied in solution at nearly 100 U / ml.
    Short-term or fast-acting insulins are soluble preparations of zinc insulin crystals dissolved in buffers of neutral pH, which are generally administered 30-45 before meals. The agent exhibits the earliest onset of action and the shortest survival.
    Insulin regulated under stable metabolic conditions is generally administered with intermediates or long-acting agents. Since medium-acting insulins have lower solubility in aqueous solutions than short-acting insulins, these insulins are destroyed more slowly after subcutaneous administration and their action time is prolonged. Two most commonly used agents NPH insulin (NPH stands for neutral protamine halide), ie suspensions of zinc-insulin crystals in phosphate buffer modified by the addition of protamine sulfate, and to minimize solubility of lente insulin, ie insulin There is an insulin suspension in acetic acid buffer modified by the addition of zinc chloride.
    Since short-acting insulin is expected to act 0.4-7 hours and medium-acting insulin is expected to work 1.5-20 hours, the choice of the amount and the appropriate time for the combination of the two types of insulin depends on a variety of factors: nutritional status, night time (fasting Consider hypoglycemia, and when the activity of antagonist-regulating hormones on hormones increases, that is, early morning hyperglycemia. When both fast-acting and long-term or medium-acting insulins are administered simultaneously, the disadvantage of this combination is that after mixing some of the fast-acting insulin complexes with excess Zn 2+ or protamine of long-term or medium-acting insulins. To medium- and long-acting insulin.
    Long-acting insulins, such as ultralente insulin or zinc-insulin or protamine-zinc-insulin suspensions, etc., are the excess of zinc, zinc and protamine added to obtain an insoluble preparation of insulin. The insulins are suspensions of small particles of zinc-insulin and differ only from one another in particle size, which is a factor in determining the action time. Unlike regulatory insulins, Ultrarente insulins are very slow initiation of action and exhibit a long action curve (flat). The insulin provides a low basic concentration of insulin during the day, but this long-term half-life makes it difficult to determine the optimal drug amount and has a long treatment duration to achieve steady-state concentrations. Ultralente insulins from cattle and pigs show a longer action than human ultralente insulins. It is preferred to start treatment three times a day as a loading, followed by one or two daily infusions.
    There are three amino groups and six carboxyl groups that can be modified in insulin. Insulin derivatives of the present invention are substituted in the A and B-chains by one or more of the radicals (i) to (iv), the terminal amino groups of Gly A1 and Phe B1 , the ε-amino groups of Lys B29 , Asn A21 and Thr Substitutions are made at one or more of the terminal carboxyl groups of B30 and / or the terminal carboxyl groups of Glu A4 , Glu A17 , Glu B13 , Glu B21 . In addition, the substituted carboxyl and / or amino insulin derivative is at least one of free hydroxyl groups of Thr A8 , Ser A9 , Ser A12 , Tyr A14 , Tyr A19 , Ser B9 , Tyr B16 , Tyr B26 , Thr B27, and Thr B30 Further substituted by one or more of the radicals (i) to (iv) above.
    In a preferred embodiment of the invention, the insulin derivative is substituted by one or more Fmoc moieties at the terminal free amino groups of Gly A1 and Phe B1 , and / or at the ε-amino group of Lys B29 , so that A 1 , B 1 and And / or an insulin derivative having a Fmoc substituent of 1-3 in B 29 , in particular the derivative is Gly A1 -N- (Fmoc) 1 -insulin, Phe B1 -N- (Fmoc) 1 -insulin , Lys B29- N- (Fmoc) 1 -insulin, Gly A1 , Phe B11 -N- (Fmoc) 2 -insulin , Gly A1 , Lys B29 -N- (Fmoc) 2 -insulin , Phe B1 , Lys B29 -N- (Fmoc) 2 -insulin and Gly A1 , Phe B1 , Lys B29 -N- (Fmoc) 3 -insulin .
    The reaction of an active Fmoc such as 9-fluorenylmethyl-N-hydroxysuccinimide (Fmoc-OSu) with insulin can give mono-, di- and tri-N-Fmoc-insulin, which is HPLC It can be easily confirmed through a process and can be obtained in purified form. In order to obtain di-N-Fmoc-insulin as the only final product, one of the free amino groups is first protected with a t-Boc group or the like, and then the protected insulin derivative is reacted with an excess of Fmoc-OSu, and then the protecting group Removal to afford the desired di-N-Fmoc-OSu. When administered to a diabetic patient, mono-, di- and tri-N-Fmoc are converted to natural insulin in vivo and exhibit antidiabetic effects for various periods of time, including long term.
    In order to replace the carboxyl group (C-Fm) of insulin, that is, the terminal carboxyl group of terminal Asn A21 and Thr B30 , and the terminal carboxyl group of Glu A4 , Glu A17 , Glu B13 , and Glu B21 , it is first necessary to use t-Boc group, Protecting the free amino group followed by three steps: (1) converting the free carboxyl group to an active ester group by reacting with o-nitrophenol or N-hydroxy-succinimide or the like; (2) reacting the active ester group with 9-fluorenylmethanol in the presence of imidazole; And (3) removing the protected t-Boc group. Another alternative method is to react the carboxyl group with N, N'-dicyclohexylcarbodiimide, 9-fluorenylmethanol and 4-dimethylaminopyridine in one step and then remove the t-Boc group.
    If a Fmoc-insulin substituent is substituted for both amino and carboxyl groups (N-Fmoc, C-Fm), the N-Fmoc substituent is prepared preferentially by reaction with Fmoc-OSu and N-Fmoc insulin and then N- Fmoc insulin is converted to active esters and then subjected to the reaction with 9-fluorenylmethanol as described above.
    In order to prepare Fm and Fmoc-insulin substituents (C-Fm, O-Fmoc) substituted with carboxyl and hydroxyl groups, the amino group is first protected with t-Boc, and the C-Fm insulin derivative is prepared as described above. And reacted with 9-fluorenylmethoxycarbonyl chloride to remove the protected Nt-Boc group.
    To prepare Fm, Fmoc-insulin substituents (N, O-Fmoc, C-Fm) substituted with amino, carboxyl and hydroxyl groups, N-Fmoc, C-Fm insulin was prepared according to the above-described method, 9 React with fluorenylmethoxycarbonyl chloride.
    The modified insulins of the present invention are prepared from insulins useful for humans, for example natural, recombinant or mutated human, bovine or swine insulins. Examples of mutated insulins are the B16-Tyr → His human insulin analogues (Kaarsholm and Ludvigsen, 1995) and the Lys B28 Pro B29 human insulin analogues (insulin lispro) that have reversed the amino acid sequences of B28 and B29 found in nature.
    Insulin lispro has the same efficacy as human insulin and is absorbed more quickly from the site of subcutaneous injection. In a preferred embodiment, the insulin is natural or recombinant human insulin.
    The mono-N-Fmoc-insulin derivatives of the invention have 40-80% of the biological potency of natural insulin, which is determined by [oly (Glu 4 Tyr)] phosphorylation assay. Di- and tri-N-Fmoc-insulin derivatives represent 2-9% and less than 1% of the biological potency of natural insulin, respectively, as determined by [Poly (Glu 4 Tyr) phosphorylation assay. When used in suitable proportions, these three forms can replace a mixture of short, medium and long-acting insulins that have traditionally been used in the subcutaneous treatment of diabetes. In the context of insulin, the present invention provides a pharmaceutical composition comprising at least one insulin derivative of the present invention and a pharmaceutically suitable carrier. For a long-acting effect, the composition preferably comprises N- (Fmoc) 3 -insulin or N- (Fmoc) 2 -insulin alone or a mixture thereof. The pharmaceutical composition is provided in a suitable formulation, such as oral formulation or subcutaneous injection.
    Another embodiment of the present invention is a method for treating diabetes comprising administering to the diabetic the at least one effective amount of the insulin derivative of the present invention. In a preferred embodiment, the derivative is a natural or recombinant human N- (Fmoc) 3 -insulin or N- (Fmoc) 2 -insulin, or a mixture thereof, which is administered at 5-8 day intervals. If necessary, treatment with Fmoc-insulin derivatives is achieved by daily administration of short-acting insulin.
    For long-term treatment, insulin is administered primarily by subcutaneous infusion. Treatment with long-acting insulin administered subcutaneously is problematic because of the large difference in absorption in diabetic patients because the additive material diffuses from the subcutaneous infusion site. The present invention provides insulin derivatives having reduced solubility by structure within the insulin molecule itself. This can eliminate large differences in subcutaneous absorption in humans and minimize or eliminate interference due to the mixing of analogs. Suitable mixtures of the three types of N- (Fmoc) -insulin described above are provided when the demand for short-acting insulin is combined with the sustained release effects of N- (Fmoc) 2 -insulin and N- (Fmoc) 3 -insulin. The duration of action can be extended and all of the insulin derivatives can be mixed without interference.
    In another embodiment of the invention, the composition of the invention comprises a mixture of mono, di and tri-N-Fmoc-insulin derivatives. N- (Fmoc) 3 -insulin is basically a long-acting insulin; N- (Fmoc) 1 -insulin shows 40-80% biological activity, which is determined by [oly (Glu 4 Tyr)] phosphorylation assay and also shows improved solubility in aqueous solution; And N- (Fmoc) 2 -insulin shows a biological activity of 2-9%, which is determined by [oly (Glu 4 Tyr)] phosphorylation assay and also shows reduced solubility in aqueous solution. The three analogues are returned to fully activated insulin by incubation at physiological pH and 37 ° C. Thus, these three suitable mixtures exhibit short, medium and long-acting effects, which are achieved by regular infusion of insulin several times with preparations comprising zinc and protamine.
    In another aspect of the invention, the prodrug is derived from a medicament for the following human or veterinary use, the invention being not limited thereto: a medicament for use in the treatment of immunological, dermatological and neurological diseases, And antidiabetic, anti-inflammatory, antibacterial, antiviral, anti-tumor and antihypertensive agents.
    The pharmaceutical composition of the present invention comprises a prodrug or a pharmaceutically suitable salt thereof and a pharmaceutically suitable carrier. Suitable methods of administration in humans and animals are, for example, traditional injection, transplantation, oral, rectal or topical administration. The formulations are prepared by conventional methods known to those skilled in the art and are described, for example, in "Remington's Pharmaceutical Science", A.R. Gennaro, ed., 17th edition, 1985, Mack Publishing Company, Easton, PA, USA.
    The invention is illustrated in detail by the following non-limiting examples.
    Biological process
    (i) Preparation of Streptozotocin (STZ) -treated Rats
    Male Wistar rats (180-200 g) were provided by the Department of Hormone Research, Weizman Institute of Science. This was then achieved by intravenous injection of freshly prepared solution of streptozotocin (55 mg / kg body weight) in 0.1 M citric acid buffer (pH 4.5) according to the method disclosed in Meyerovitch et al., 1987 to induce diabetes.
    (Ii) concentrated preparation of insulin receptor tyrosine kinase
    The enzyme was obtained from rat liver cell membrane according to the method disclosed in Meyerovitch et al., 1990. First, hepatocytes were homogenized in the presence of protease inhibitors, lysed with 1% Trition X-100 and then centrifuged. The supernatant was then passed through a malt aglutinin (WGA) -agarose column (Sigma). The adsorbed insulin receptor portion was then eluted with 0.3 mM N-acetyl-D-glucose amine in 50 mM HEPES buffer, pH 7.4, containing 0.1% Trition X-100, 10% glycerol and 0.15M NaCl. Biological efficacy of insulin and insulin derivatives was evaluated according to the assays of (iii) and (iii) below.
    (Iii) Lipidogenesis (insertion of labeled glucose into lipids in complete adipocytes)
    Rat adipocytes were prepared according to the method of Rodbell, 1964. Fat pads of male Wistar rats were cut into small pieces using scissors, NaCl, 110 mM; NaHCO 3 , 25 mM; KCl, 5 mM; KH 2 PO 4 , 1.2 mM; CaCl 2 , 1.3 mM; MgSO 4 , 1.3 mM; And 3 ml KRB buffer containing 0.7% BSA pH 7.4. Collagenase (1 mg / ml) was decomposed with vigorous stirring at 37 ° C. for 40 minutes in a 25 ml flexible plastic bottle under a carbogen (95% O 2 , 5% CO 2 ) atmosphere. 5 ml of buffer was added and the cells passed through a sieve screen. Cells were then left to stand in water in 15 ml plastic in vitro for a few minutes, floated and bottom buffer removed. The procedure (suspension, floating and bottom buffer removal) was repeated three times.
    Adipocyte suspension (3 × 10 5 cell counts / ml) was separated into plastic vials (0.5 ml per vial) and with or without insulin for 60 minutes in a carbogen atmosphere with 0.2 mM [U- 14 C] glucose. Incubated at 37 ° C. Lipid formation was terminated by adding toluene-based scintillation solution (1.0 mL per vial) and radioactivity of the extracted lipids was measured (Moody et al., 1974). In a typical experiment, insulin-stimulated lipid production was 4-5 times higher than the default value (default 2000 cpm per 3 × 10 5 cells / hour; V insulin 8,000-10,000 cpm per 3 × 10 5 cells / hour). In this assay, insulin stimulated lipid production with ED 50 value = 0.15 ± 0.03ng / ml (Shechter and Ron, 1986). Insulin analogs that exhibit an ED 50 value = 15 ng / ml are considered to have about 1% of the biological potency of natural insulin.
    (Iii) Determination of receptor tyrosine kinase activity
    In this assay insulin stimulates its receptors to phosphorylate random copolymers containing L-glutamic acid and L-tyrosine in a 4: 1 molar ratio [Glu 4 Tyr]. Standard enzyme assay mixtures (with a final volume of 60 μl and in 50 mM Hepes containing 0.1% Triton X-100) were WGA purified insulin receptor (5 μg protein), 20 mM MgCl 2 , 2 mM MnCl 2 , 100 μM ATP and various Insulin or insulin derivatives at a concentration (1 ng / ml-10 mg / ml). After 30 min preincubation at 22 ° C., poly (Glu 4 Tyr) (final concentration 0.7 mg / ml) was added to initiate the reaction, which proceeded at 22 ° C. for 20 minutes and EDTA (20 mM) was added. The reaction was terminated by doing so. The amount of phosphotyrosine in the polyGlu 4 Tyr was quantified using radio-immunoassay using a specific monogroup antibody against phosphotyrosine (final dilution 1: 100,000) and a 125 I-BSA-phosphotyrosine conjugate. In this assay insulin promoted a half-maximal effect at a concentration of 20 ± 3 ng / ml. Insulin analogs that exhibit an ED 50 value = 2 mg / ml are considered to have about 1% of the biological potency of natural insulin.
    Example 1 Preparation of N-Fmoc-Insulin Derivatives
    (a) synthesis
    Human insulin (100 mg, 17.2 μmoles) (provided by Biotechnology-General, Rehovot, Israel) was suspended in 4 mL of analytical dimethylformamide (DMF) containing 17.4 mg (172 μmoles) thiriethylamine. Then Fmoc-OSu (58 mg, 172 μmoles) was added. The homogeneous reaction mixture was stirred at 25 ° C. for 20 hours and ethyl acetate was added until the solution was cloudy, followed by ether to complete the precipitation. Then the solvent was removed by centrifugation and the precipitate was washed twice with ether twice with water. This procedure yielded a mono, di and tri-N-Fmoc-insulin mixture, which was isolated and purified using preparative HPLC. Monomodified N-Fmoc-insulin derivatives are separated into di and trimodated insulin derivatives by washing the crude solid with isopropanol.
    (b) Isolation and Purification of N-Fmoc-Insulin Derivatives
    Crude solids were loaded into reverse phase HPLC (Spectra-Physics SP 8800 liquid chromatography system) equipped with HPLC prepack column (Merck, LIChrosCART 250-10 mm with LIChrosorb RP-18 [7 μm]). Linear gradient of acetic acid (TFA) (solution A) and acetonitrile with 0.1% trifluoroacetic acid in H 2 O: was formed with a 0.1% TFA (solution B) in H 2 O, 75:25. The flow rate was 1 ml / min. N- (Fmoc) 1-insulin derivative was eluted at a retention time of 21.1, 21.9 and 22.8 minutes, N- (Fmoc) 2-insulin derivative is N- (Fmoc) 3 in the hold time of 26.3, 27.1 and 27.7 minutes Insulin Eluted at 31.5 minutes. The sections corresponding to the retention time 21-23 minutes, 26-28 minutes and 31.5 minutes were collected, lyophilized and checked for chemical properties. Portions corresponding to retention times 21-23 minutes (monomodified insulin) and 26-28 minutes (dimodified insulin) were further purified to obtain mono-Fmoc and di-Fmoc insulin derivatives, respectively. The amount of Fmoc group bound to the insulin molecule was determined by treatment with a known amount of N-Fmoc-insulin derivative with 50% piperidine in CH 2 Cl 2 , followed by spectrophotometry at 301 nm.
    (c) Chemical Properties of N-Fmoc-Insulin Derivatives
    Following separation by HPLC, seven N-Fmoc-insulin derivatives were obtained. It comprises three monomodified, three dimodified and one trimodified derivatives, respectively (Table 1). The retention time and yield of each compound are shown in Table 1. The different N-Fmoc-insulin derivatives could be easily separated and purified under laboratory conditions. Phe B1 , Lys B29 -N- (Fmoc) 2 -insulin (holding time = 27.7 minutes) and Gly A1 , Phe B1 , Lys B29 -N- (Fmoc) 3 -insulin are subjected to several processes including mass spectra. The characteristics were confirmed (Table 1).
    (d) Synthesis of Phe B1 , Lys B29 -N- (Fmoc) 2 -insulin
    Biological analysis shows that Phe B1 , Lys B29 -N- (Fmoc) 2 -insulin is particularly suitable for long-acting insulin and has found other ways to synthesize it. The Gly A1 site was protected under t-Boc groups with 1 equivalent of di-tert-butyldicarbonate and DMSO / Et 3 N, 20: 1 under laboratory conditions. After separation by HPLC procedure, Gly A1 -N-Boc-insulin was reacted with excess Fmoc-OSu (10 equiv), DMF as solvent and DIEA as base. Phe B1 , Lys B29 -N- (Fmoc) 2 -insulin was prepared in good yield (about 50%) by treatment with TFA and purification by HPLCdp.
    (e) Investigation of biological properties of N-Fmoc-insulin derivatives
    Several properties of the N-Fmoc-insulin derivatives of the present invention are summarized in Tables 2 and 3. The solubility of the derivatives in aqueous solution decreased with increasing strain. N- (Fmoc) 1 -insulin derivatives showed slightly lower solubility than natural insulin, and N- (Fmoc) 3 -insulin derivatives showed about 20 times lower solubility than natural hormones. In addition, as the modification increased, the biological efficacy also decreased. Thus, mono, di and tri-N-Fmoc-insulin exhibited 40-80%, 2-9% and <1% of the biological potency of natural insulin, respectively, which was determined by [Glu 4 Tyr] phosphorylation assay. Confirmed. More sensitive biological analysis of adipogenesis using complete rat adipocytes shows that Fmoc-insulin derivatives exhibit lower biological efficacy. Thus, using the lipid production assay, Gly A1 -N-Fmoc-insulin and di-N-Fmoc-insulin showed 4.7% and 0.4-1.4% of the biological efficacy of natural insulin, respectively (Table 3). . All seven derivatives return to natural hormones by incubating at pH 8.5 for 2 days. This was confirmed by complete recovery of biological efficacy (Tables 2 and 3) and disappearance of derivative peaks through HPLC analysis and the appearance of natural hormonal peaks (holding time = 15 minutes).
    Chemical Properties of N-Fmoc-Insulin Derivatives derivativeHold time (HPLC), minutes a) Yield b) (%)Mole Fmoc / Mole InsulinFmoc insertion positionMass spectrum (molecular weight), calculated as [M + H] +N- (Fmoc) 1 -insulin21.130.8Gly a1 N- (Fmoc) 1 -insulin21.961.2Lys b29 N- (Fmoc) 1 -insulin22.840.9Phe B1 N- (Fmoc) 2 -insulin26.3121.7Gly A1 , Lys B29 N- (Fmoc) 2 -insulin27.162.14Gly A1 , Phe B1 N- (Fmoc) 2 -insulin27.7141.9Phe B1 , Lys B29 6252 6255 N- (Fmoc) 3 -insulin31.5303.4Gly A1 , Lys B29 , Phe B1 6474 6475
    Note: Amino acid analysis demonstrates the correct composition of all Fmoc-insulin derivatives.
    a) 100% solution B from 60% solution A (0.1% TFA in water) and 40% solution B (75:25, acetonitrile: 0.1% TFA in water) for 40 minutes (flow rate, 1 ml / min) Measured using Merck, LiChrospher 100 RP-8 (5 μm) column linearly gradient over
    b) based on pure water obtained according to HPLC
    Representative Properties of N-Fmoc-Insulin Derivatives derivativeoriginFmoc insertion positionExternal appearance in buffer solutionSolubility in buffered solution (pH 7.4, mg / mL)Biological efficacy (%)Biological efficacy after incubation (2 days, 37 ° C, pH 8.5) Natural insulinhuman SunnyAbout 4 or more100100 N- (Fmoc) 1 -insulinhumanGly a1 Almost sunnyAbout 340 ± 295 N- (Fmoc) 1 -insulinhumanLys b29 Almost sunnyAbout 378 ± 494 N- (Fmoc) 1 -insulinhumanPhe B1 Almost sunnyAbout 376 ± 495 N- (Fmoc) 2 -insulinhumanGly A1 , Lys B29 blurAbout 22 ± 193 N- (Fmoc) 2 -insulinhumanGly A1 , Phe B1 blurAbout 23 ± 197 N- (Fmoc) 2 -insulinhumanPhe B1 , Lys B29 blurAbout 29 ± 295 N- (Fmoc) 3 -insulinhumanGly A1 , Lys B29 , Phe B1 Very cloudyAbout 0.2<198
    Note: Insulin potency was performed according to the two biological assays disclosed in the above examples.
    Time-Dependent and Biological Efficacy of N-Fmoc-insulin Derivative Activity Using Lipidogenesis Assay (with Complete Fat Adipose Cells) derivativeED 50 lipogenesis ng / mlRelative Biological Efficacy (%)Activity after incubation (%; pH 8,5, 37 ℃) 9 hours20 hours45 hours Natural insulin0.2-0.4100 Gly A1 -N- (Fmoc) -insulin74.750100Gly A1 , Lys B29 -N- (Fmoc) 2 -insulin 440.4102097 Gly A1 , Phe B11 -N- (Fmoc) 2 -insulin301.11840100 Phe B1 , Lys B29 -N- (Fmoc) 2 -insulin 12.31.4102098
    Example 2. Biological Activity of N-Fmoc-insulin
    (a) Activity over time of N-Fmoc-insulin at pH 7.4
    Prior to the study of the antidiabetic effects of N-Fmoc-insulin in diabetic rats, their rate of reactivation (conversion to natural hormones) was confirmed in vitro. The derivative was dissolved in Hepes buffer (50 mM, pH 7.4) containing 10% dimethylsulfoxide (DMSO) and then incubated at 37 ° C. (physiological pH and body temperature). At some point a portion was harvested to determine the relative biological potency for natural insulin. Biological activity was confirmed through insulin receptor tyrosine kinase activity (cell free assay described in the biological process of (iii) above) and stimulation of lipid production in the complete rat adipocytes described in the biological process, (ii). The results are shown in FIG. Half maximal activity was seen at t 1/2 = 14 days for N- (Fmoc) 3 -insulin, and nearly maximal activity was observed following incubation for 21 days.
    Regularly, the rate of activity of N- (Fmoc) 2 -insulin at pH 7.4 increased. The 6-day delay observed with N- (Fmoc) 3 -insulin was not observed with N- (Fmoc) 2 -insulin. Thus, it was found that N- (Fmoc) 3 -insulin has a Fmoc moiety that is more slowly hydrolyzed to limit reactivation. After the hydrolysis, the rate of activity increases. In practical terms, one can assume that a mixture of the two analogs can release active insulin for an extended period of time, including early and late. The relatively active monomodified Fmoc-insulin recovered the maximum biological potency at pH 7.4 and t 1/2 = 5 days.
    It is speculated that when N- (Fmoc) 2 -and N- (Fmoc) 3 -insulin reach the circulatory system, it will provide low basic concentrations of hormones for a long time. This is mainly determined by the rate of conversion of the inactive derivatives to active short-lived natural hormones. Fortunately, N- (Fmoc) 2,3 -insulin has a slow activation rate (see FIG. 1). Fast pace (in minutes) results in hypoglycemia.
    Phe B1 , Lys B29 -N- (Fmoc) 2 -insulin shows 9% biological activity, which is confirmed by [oly (Glu 4 Tyr)] phosphorylation assay, and also of natural insulin and N- (Fmoc) 3 -insulin Moderate solubility. Unlike N- (Fmoc) 3 -insulin, the conversion of N- (Fmoc) 2 -insulin to natural insulin begins (in a few hours) immediately after incubation, as can be seen in FIG. Thus, it can be inferred that N- (Fmoc) 2 -insulin has a faster onset of action after administration. Thus, suitable combinations of N- (Fmoc) 2 -and N- (Fmoc) 3 -insulin provide an ideal formulation for the release of basic insulin, which is characterized by fast onset of action and prolonged duration of post-administration. Configure preferred embodiments of the invention.
    Effect of Intraperitoneal Administration of Phe B1 , Lys B29 -N- (Fmoc) 2-insulin on Daily Weight Gain in STZ Rats groupTechnologyDaily weight gain / rat (first 3 days) A (n = 5)STZ rats (2.0 ml, 20% DMSO / rat) administered only excipients2.0 ± 0.2 B (n = 5)STZ rats intraperitoneally administered NPH-human insulin (Hullin N, 3 mg / rat)12.0 ± 2 C (n = 5)STZ rats intraperitoneally administered N- (Fmoc) 2-insulin (3 mg / rat)11.5 ± 1.3
    (b) Effect of intraperitoneal administration of Phe B1 , Lys B29 -N- (Fmoc) 2 -insulin alone on normal rats
    (Fmoc)2Additional in vivo assays were performed to confirm long-term ability to act due to slow conversion to natural hormones under physiological conditions of insulin. This assay shows long-acting characteristics after subcutaneous administration of insulin (or insulin derivatives) in the circulation. Natural Insulin, NPH-insulin and (Fmoc) in Normal Rats2Insulin (3 mg / rat) was injected alone intraperitoneally and blood glucose levels were measured over 3 days. The results are shown in FIG. Natural insulin (FIG. 3) and NPH-insulin (FIG. 2) induced hypoglycemia for about 12 and 15 hours, respectively. Recovery from hypoglycemia is t each1/2= 8 hours and 10 hours. (Fmoc)2Insulin reduced blood sugar levels for about 48 hours, and recovery from hypoglycemia was t1/2= 26 hours. The result is (Fmoc)2The extended action of insulin is supported by its intrinsic properties and slow entry into the circulatory system, indicating that it is not by the traditional mechanism of NPH-insulin, ie by precipitation at the injection site. As expected, the difference in the ability of natural insulin and NPH-insulin to reduce blood glucose levels is small compared to the case by subcutaneous administration. This result is due to the rapid conversion of large amounts of liquid and zinc-crystalline insulin into monomeric form in the abdominal cavity. The other two (Fmoc)2-Insulin derivatives, ie [GlyA1, LysB29] And [GlyA1, PheB11] Was synthesized and the assay described above was performed. As a result (not listed) t of 22-24 hours for both derivatives1/2, PheB1, LysB29-N- (Fmoc)2It exhibited a long-acting pattern similar to insulin.
    (c) Proteolytic Resistance of N- (Fmoc) 3 -insulin
    Natural insulin or N- (Fmoc) 3 -insulin (1 mg / ml each in 50 mM Hepes, pH 7.4, 10% DMSO) was incubated at 37 ° C. Then chymotrypsin and trypsin (0.5% w / w respectively) were added. A portion was recovered at the designated time and an analytical HPLC procedure was performed. The degradation rate was determined using a decrease in the peak area of native insulin (hold time 15 minutes) or N- (Fmoc) 3 -insulin (hold time 31.5 minutes). The results are shown in FIG.
    N- (Fmoc) 3 -insulin was found to show a strong resistance to proteolysis by a mixture of chymotrypsin and trypsin at pH 7.4. Natural insulin and N- (Fmoc) 3 -insulin showed t 1/2 of 0.5 hour and 7.5 hours, respectively, and the proteolysis proceeded.
    Example 3 Effect of Subcutaneous Administration of Phe B1 , Lys B29 -N- (Fmoc) 2 -insulin and N- (Fmoc) 3 -insulin on STZ-diabetic Rats
    STZ rats are a good model of in vivo insulin therapy. In this model, about 90% of β-cells were destroyed by streptozotomycin, which was confirmed by anatomical examination (Pederson et al, 1989). Rats had hypoinsulinemia (10-30% of normal insulin), hyperglycemia (greater than 300 mg / dL; normal glucose in control rats was 90-100 mg / dL) and metabolism was metabolism side. The appearance of the disease was visible as a symptom of appearance, and water absorption and excretion of urine increased by 3-4 times. Daily weight gain was about 10-20% less than the normal daily weight gain (0.3-0.8 g / day / rat) of the control. Pathological changes in the tissues of the STZ-rat occurred significantly. More clear biochemical changes are an increase in insulin binding capacity that does not involve a decrease in major enzymes in glycogen metabolism, a lack of hepatic glycogen, a decrease in the number of glucose transporters in peripheral tissues and an increase in responsiveness to insulin.
    In the diabetic rat model, easy insulin treatment is one week of continuous administration of insulin (5 units / day / rat). The treatment normalizes blood glucose levels, returns diabetic rats towards anabolic metabolism, and reduces many pathological symptoms caused by hyperglycemia and hypoinsulinemia. Administration of fast-acting (regular) insulin alone is only effective for several hours. In addition, the 7-day treatment ends and hyperglycemia recurs within 24-30 hours.
    To confirm the prolonged antidiabetic effect of N- (Fmoc) 3 -insulin, STZ-rats were treated with natural insulin (Group A, 25 units, 10 ml H 2 0-10% DMSO 2 weeks after diabetes induction). Dissolved 1 mg, n = 4), or N- (Fmoc) 3 -insulin (Group B, 1 mg dissolved in 10 mL H 2 0-10% DMSO, n = 4) alone was subcutaneously injected. Blood glucose levels and daily weight gains were observed for 7 days.
    The results are shown in FIG. Each point represents the arithmetic mean ± SEM of 4 rats of plasma glucose. Circulating glucose in group B was significantly decreased. From the second day after the administration, the blood glucose level was decreased by 90-110 mg / dl in group B, and the decrease was continued until day 6. On day 7, there was no significant difference in circulating glucose in the two groups of rats. Rats administered N- (Fmoc) 3 -insulin were healthy in appearance. Daily weight gain increased almost threefold in group B, with 0.57 ± 0.08 and 1.43 ± 0.14 g / rat / day in group A and B, respectively. Thus, it was found that administration of N- (Fmoc) 3 -insulin alone showed prolonged antidiabetic action for 4 days (following delayed onset of about 2 days). The long-lasting effect in vivo is due to the receptor-mediated endocytosis avoidance ability of the derivatives and resistance to proteolysis. Moreover, N- (Fmoc) 3 -insulin is generally insoluble in aqueous solution. Thus, in humans, the overall sustained effect can be achieved by replacing conventional therapeutic principles, namely the gradual dissolution of the prepared insoluble insulin, with a new principle of subcutaneous administration, ie, circulating long-lived covalently modified inactive insulin derivatives. The insulin derivative is slowly converted to natural hormones. Since the insulin derivative is inactive, a larger amount can be administered without concern for hypoglycemia.
    To confirm the effect of Phe B1 , Lys B29 -N- (Fmoc) 2 -insulin on reducing blood glucose levels in experimental diabetic rats, ie STZ-treated rats, N- (Fmoc) 3 -insulin 9 days after induction of diabetes. (Group A, 3 mg / rat dissolved in 2.0 ml 20% DMSO, n = 5), or long-acting insulin (NPH-human insulin, humulin N, HI-310) (group B, 0.75 ml per rat ( 3 mg), n = 5) was injected subcutaneously alone. Group C was administered only excipient (2.0 mL 20% DMSO). Blood glucose levels were measured daily.
    The results are shown in Figure 6, the dashed line means the arithmetic mean of the plasma glucose of the control rats. As can be seen in FIG. 6, subcutaneous administration of Phe B1 , Lys B29 -N- (Fmoc) 2 -insulin purified by HPLC induces normal blood glucose for 4 days and increases the daily weight gain of catabolic STZ-rats. It can be seen (Table 3). N- (Fmoc) 2 -insulin was as effective as commercialized long-acting (insoluble) agents. Short-acting (soluble) insulin induced blood glucose reduction for only 7 hours. The formulations dissolve well in aqueous solution (pH 7.4), which is advantageous in that suspensions of insoluble N- (Fmoc) 2 -insulin cannot be precisely administered by subcutaneous injection.
    Example 4 Preparation and Biological Activity of (2-Sulfo) Fmoc-Insulin
    (a) Synthesis of (2-sulfo) Fmoc-insulin (Sulfmoc-insulin)
    The Fmoc group itself was modified to change the hydrophobicity of Fmoc-insulin, increase its solubility and rate of reconversion to insulin. Said modification is effected by introducing polar, preferably charged groups, into fluorene rings such as halogen, nitro, carboxyl, amino, ammonium and sulfo groups. In electron-affinity substitution reactions, fluorene is attacked at the first two positions, and generally the nature of the substituent at position 9 (eg CH 2 OCO-OSu) does not affect the orientation of the substitution. Fmoc-OSu was treated with 0.9 equivalents of chlorosulfonic acid in dichloromethane (DCM) at 0 ° C. to yield high yield (R 1 = SO 3 H at position 2 , R 2 = R 3 = R 4 =). (2-sulfo) Fmoc-OSu was obtained with H, A = OCO-OSu). In the case of treatment with 1 equivalent or more, the position 7 of the fluorene ring is also substituted.
    The (2-sulfo) Fmoc group was introduced into insulin by coupling the active (2-sulfo) Fmoc-OSu ester to the amino group of insulin. The reaction was performed under conditions of aqueous buffer (pH 7.4) and excess reagent (about 20 equivalents). After dialysis and lyophilization, the product became water soluble. HPLC analysis showed one main product and confirmed (Sulfmoc) 2 -insulin via mass-spectrum (m / z 6411). When the reaction was carried out under acetonitrile / water, 1: 1 conditions, the main product was (Sulfmoc) 3 -insulin, confirmed by mass-spectrum (m / z 6713).
    (b) Activity over time of (2-sulfo) Fmoc-insulin
    (Sulfmoc) 2 -insulin was completely converted to natural hormones by incubation for 36 hours at pH 8.5 (0.1M NaHCO 3 ) and 37 ° C, or for 36 hours at pH 7.4 (50mM Hepes buffer), T 1/2 was 12-15 hours and 6 days, respectively. HPLC analysis showed that the insulin derivative peak disappeared and a natural hormonal peak appeared. Hydrolysis of (Sulfmoc) 2 -insulin to natural hormone proceeded faster than hydrolysis of (Fmoc) 2 -insulin (pH 7.4, 21 days at 37 ° C.).
    (Sulfmoc) 2 -insulin has a biological activity of 0.5% and has good solubility in water. Upon incubation at pH 8.5 and 37 ° C., (Sulfmoc) 2 -insulin was completely converted to natural hormones, where t 1/2 was 4-6 hours each, indicating a time-dependent increase in biological efficacy (rat fat Lipid production analysis in cells).
    (c) Effect of Intraperitoneal Administration of (2-sulfo) Fmoc-insulin on Normal Rats
    To investigate the long-term function of (Sulfmoc) 2 -insulin, normal rats were injected with natural insulin, NPH-insulin or (Sulfmoc) 2 -insulin alone intraperitoneally and blood glucose levels were measured over two days. 3 shows that (Sulfmoc) 2 -insulin induces hypoglycemia for 24 hours. Return from hypoglycemia occurred at t 1/2 = 14 hours. For short term and NPH-insulin, t 1/2 was 8 (FIG. 3) and 10 o'clock (FIG. 2), respectively. Thus, administration of (Sulfmoc) 2 -insulin alone shows medium antidiabetic action, which is 1.5-2 hours longer than short or NPH-insulin. The results are consistent with the increased hydrolysis rate of Sulfmoc-insulin in vitro. The sulfonic acid at position 2 of the fluorene ring increases the removal rate of H + at position 9 2-3 times, thereby increasing the rate of hydrolysis at the Sulfmoc site by 2-3 times. Studies on the effects of sulfoc groups on multiple bases show more sensitive base sensitivity than the parent system. Moreover, the release rate constant of sulfmoc groups from glycine was greater than that of Fmoc groups (about 30 times). Thus, increased solubility with the introduction of sulfmoc groups in insulin reduces the long-lasting effect of this derivative. The long-lasting antidiabetic effect achieved by avoiding receptor-mediated endocytosis and degradation mechanisms also applies to Sulfmoc-insulin.
    Increasing the rate of sulfmoc group removal from insulin is an advantage when applying insulin administration such as medium-term preparations. Such formulations have the advantage of being completely dissolved in aqueous buffer as opposed to commercialized formulations. It is also possible to introduce other functional groups of varying acidity or polarity into the fluorene ring. Thus, by controlling the type and number of functional groups introduced into the Fmoc group, the solubility and reactivation rate of the modified insulin can be controlled.
    Example 5 Preparation of Amino and Carboxyl-Terminal Modified Insulins (N-Fmoc- and C-Fm-insulin Derivatives)
    N- (Fmoc) 3 -insulin (64.5 mg; 10 μmol; 60 μmol carboxyl site, ie 4 Glus in the chain and two C-terminal residues) was added o-nitrophenol (250 μmol; 35 mg) or N-hydroxysuccini It was dissolved in 8 ml of dimethylformamide (DMF) with amide (250 μmol; 28 mg) (Lab. Scan., Dublin, Ireland) and then cooled to 4 ° C. A solution of N, N-dicyclohexylcarbodiimide (DCC; 250 mmol, 53 mg) in 0.5 mL of DMF was added and the reaction mixture was left at 4 ° C. for 1 hour and then left at room temperature for 6 hours. The precipitated N, N-dicyclohexyl urea was removed by centrifugation and the o-nitrophenyl or N-hydroxysuccinimide esters of N- (Fmoc) 3 -insulin were respectively precipitated by drying, cooling and ether. I was. The solid was then washed twice with dried ether and dissolved in 8 ml of DMF. Then a solution of 9-fluorenylmethanol (250 μmol; 50 mg) and imidazole (250 μmol; 17 mg) dissolved in 1 mL of DMF was added. The reaction mixture was allowed to stand overnight at room temperature. Precipitation with dried ether gave 62 mg of N- (Fmoc) 3 , C- (Fm) n -insulin. The main product is hexa-9-fluorenylmethyl ester C- (Fm) 6 (n = 6) of N- (Fmoc) 3 -insulin.
    Example 6 Preparation of Carboxyl-Terminal Fm-Insulin (C-Fm-Insulin)
    For the preparation of t-butyloxycarbonyl (t-Boc) 3 -insulin, di-tert-butyldicarbonate (56 mg, 258 μmol) was added insulin (100 mg, 17.2 μmol) in ice-cooled, stirred DMF (4 mL). ) And triethylamine suspension (174 mg, 172 μmol). The reaction mixture was allowed to warm to room temperature and then stirred for 5 hours (gradually cleared). Ethyl acetate was then added until the solution was cloudy, then ether was added and the precipitate was centrifuged and washed again with ether. The crude solid thus produced (95 mg) was used without further purification. Analytical HPLC confirmed that the main product eluted at 27.5 minutes.
    The product was dissolved in 10 ml of DMF and then treated with o-nitrophenol or N-hydroxysuccinimide to give the corresponding active ester. The ester was then treated with 9-fluorenylmethanol in the presence of imidazole and then precipitated with dry ether to give N- (t-Boc) 3 , C- (Fm) n -insulin in powder form ( 87 mg). The powder was dried in vacuo on P 2 O 5 and then treated with 5 ml of trifluoroacetic acid at room temperature for 1 hour to remove the N-terminal t-Boc protecting group. Most of the insulin derivative was dissolved during this process. Ice-cooled and dried ether was then added and centrifuged to separate the powder and washed vigorously with dried ether. The product was mainly C- (Fm) 6 -insulin, the yield was 79 mg.
    Example 7 Preparation of (Fmoc) 1-Human Growth Hormone (Fmoc 1- hGH)
    Under normal physiological conditions, hGh levels in healthy individuals increase pulsating (day and night) several times daily. hGH is a short-lived hormone. Currently used treatments are single daily infusions of hGH, which are effective for only a few hours. Therefore, it is highly desirable to develop long-acting (sustained release) hGH formulations that can supply a threshold-base amount of hGH for 24 hours during the day and night.
    Natural hGH (Biotechnology General, Rehovot, Israel; 9.2 mg) was dissolved in 0.1 M NaHCO 3 (2.0 mL; pH 8.5), DMSO (0.1 mL) was added (concentration of final DMSO, about 5%), 0 Cool to C. 10 μl of Fmoc-OSu equivalent (taken from 18.5 mg / ml stock solution in DMSO) was then added and the reaction proceeded for 30 minutes at 0 ° C. with moderate stirring. Then 10 μl of Fmoc-OSu 1 equivalent was added again, and after 30 minutes the mixture was dialyzed overnight at 7 ° C. against H 2 O. HPLC showed peaks corresponding to natural hGH (about 20% of total; retention time 30 minutes; RP-8 column; 250 × 10 mm; Merck) and modified Fmoc-hGH (about 80% of total; retention time 32 minutes). Confirmed.
    Table 5 shows that Fmoc-hGH (1 mg / mL) converts to natural hGH when incubated at 37 ° C. in 0.1 M NaHCO 3 (pH 8.5). A portion was recovered at the designated time and analytical HPLC (RP-8 column) was performed. Conversion of Fmoc-hGH to natural hGH was confirmed by increasing the peak area corresponding to natural hGH.
    As can be seen in Table 5, Fmoc-hGH has 15% of the receptor-binding capacity of natural hormones. Fmoc-hGH was incubated at pH 8.5 (37 ° C.) for about 6 days or at pH 10.5 (37 ° C.) for 4 days to obtain fully activated hGH, which was confirmed by receptor binding analysis and HPLC analysis.
    Production of natural hGH from Fmoc-hGH during incubation (37 ° C) compoundprocessIodide hormone replacement ability 1) (%)conversion to hGH 2) (%) hGH 100Fmoc-hgh 15Fmoc-hgh1 day, pH 10.525Fmoc-hgh4 days, pH 10.5100Fmoc-hgh1 day, pH 8.5 23 Fmoc-hgh2 days, pH 8.5 62 Fmoc-hgh6 days, pH 8.5 100
    (1) Iodide hormone replacement was performed according to Gertler et al., 1984. Natural hGH was very stable at the conditions applied to Fmoc-hGH (pH 10.5, 37 ° C. and 4 days).
    (2) Fmoc-hGH (1 mg / ml) was incubated at 0.1 M NaHCO 3 (pH 8.5) and 37 ° C. A portion was recovered at the designated time and subjected to analytical HPLC. The conversion from Fmoc-hGH to native hGH was measured through an increase in the peak area corresponding to native hGH.
    Example 8 Preparation of N-Fmoc-Separexin and Separexin-O-Fm Ester
    Separexine [7- (D-α-aminophenylacetamido) desacetoxyceparosporanic acid] has a broad spectrum of activity against gram (-) and gram (+) bacteria as β-lactam antibiotics. Two types of monosubstituted separexins were prepared, in which the fluorenylmethyl (Fm) moiety was covalently bonded to an amino group (N-Fmoc-separexin) or a carboxyl group (separexin-O-Fm), i.e., esterification Is manufactured through.
    (i) (a) Preparation of N-Fmoc-Separexin
    Fmoc-OSu (145 mg, in DCM) (2.5 ml) to a stirred suspension of separexin hydrate (Sigma, USA; 50 mg, 0.144 mmol) and triethylamine (29 mg, 0.288 mmol) in dichloromethane (DCM; 2.5 ml) 0.432 mmole) solution was added dropwise for 5 minutes. The reaction mixture, which was cleared after 1 hour, was stirred at room temperature overnight, which became cloudy again. Concentrated in vacuo, then ether was added and the resulting precipitate was filtered off and washed twice with ether. The filtrate was dissolved in DCM, extracted with acidified water (about pH 2), water and brine and dried over anhydrous MgSO 4 . Then filtered and concentrated, then ether was added. The precipitate was filtered and washed with ether to give pure Fmoc-Separexin, which was purified by TLC (1-butanol: acetic acid: water, 8: 1: 1) and analytical HPLC (eluted at 33 min, natural separexin under the same conditions). Eluted at 6.5 min). Mass spectra (Fast Atom Bombardement, FAB) analysis gave the expected molecular weight of N-Fmoc-Separexin (M / Z 570.1 [M + H] + ).
    (i) (b) Antimicrobial Activity of Fmoc-Separexin
    Staphylococcus aureus (0.5 ml / glass tube) with or without increasing the concentration of natural Sephaplexin or Fmoc-Separexin, to determine the antimicrobial activity of native Sepapexin and Fmoc-Separexin Test tubes containing a thin suspension of were incubated at 37 ° C. for 6 hours, followed by the treatments described in Table 6. Partials were withdrawn at the indicated time and analyzed for bacteriostatics against Staphylococcus aureus. Bacterial growth was determined by observing increased turbidity at 700 nm with a spectrophotometer.
    Antimicrobial Activity of Natural Separexin and N-Fmoc-Separexin compoundIncubation (pH 7.4, 37 ℃)Concentration at 50% inhibition of bacterial growth (μ 50 ) (IC 50 )Antibacterial activity 1) (%) Nature separexin---0.9100 Nature separexin1 day1.5100 Nature separexin3 days5.3100 Nature separexin6 days18100 Fmoc-Separexin---236 Fmoc-Separexin1 day1510 Fmoc-Separexin3 days959 Fmoc-Separexin6 days4.5100
    (1) Numbers indicate the efficacy of Separexin used as a control in the analysis. Incubation was performed at pH 7.4 with native Separexin or N-Fmoc-Separexin (100 μg / ml) in 50 mM Hepes buffer, 20% DMSO.
    As can be seen in Table 6, N-Fmoc-Separexin was not active (about 6%). Natural ceparexin was formed by pre-incubation (pH 7.4, 37 ° C.) for 6 days, which was confirmed by HPLC and about 50% recovery of the antimicrobial activity of the parent compound. Natural ceparexin showed significant time-dependent natural inactivation upon incubation, whereas N-Fmoc-separexin showed more stable properties under the same conditions. Thus, it can be seen that the prolonged action of N-Fmoc-Separexin in vivo is due to improved chemical stability under physiological pH and temperature in addition to its ability to avoid degradation mechanisms. N-Fmoc-Separexin has more stability against hydrolysis by penicillinase than the parent compound.
    (Ii) Preparation of Separexin-O-Fm Ester (Separexin Fluorenylmethyl Ester)
    (a) N-Boc-Separexin
    Di-tert-butyl dicarbonate (94.2 mg, in DCM) (2.5 mL) in a stirred ice-cooled suspension with separexin hydrate (50 mg, 0.144 mmole) and triethylamine (29 mg, 0.288 mmole) in DCM (3 mL) 0.432 mmol) solution was added. The reaction mixture was warmed to room temperature and stirred overnight by TLC (1-butanol: acetic acid: water, 8: 1: 1) until no nihydrin-positive starting material was detected. The reaction mixture was then diluted with DCM (2.5 mL), extracted with acidified water (about pH 2), water and brine, and dried over anhydrous MgSO 4 . After concentration it was precipitated by addition of petroleum ether (boiling point 40-60 ° C.), then filtered and washed with petroleum ether. The product was uniform, which was confirmed by TLC and HPLC.
    (b) Separexin-O-Fm ester
    To an ice-cooled stirred solution of N-Boc-Separexin (25 mg, 0.056 mmol) 9-fluorenylmethanol (22 mg, 0.112 mmol) and 4-dimethylaminopyridine (13.7 mg, 0.112 mmol) in DCM (2.5 mL) ) Was instilled for 20 minutes. The mixture was then stirred at room temperature and filtered to remove dicyclohexylurea. The filtrate was diluted with DCM (2.5 mL) and extracted with 1M NaHCO 3 solution, 10% citric acid, water and brine, then dried over anhydrous MgSO 4 . The solution was then evaporated to give an oily solid, which was triturated with petroleum ether to give Boc-Separexin-OFm (check by TLC and HPLC). The Boc site was removed by dissolving crude solid (25 mg) in a 1 ml solution of TFA: DCM (1: 1 v / v). After standing at room temperature for 20 minutes, the TFA was removed by evaporation, the solid residue was dissolved in isopropanol and the isopropanol was evaporated. Repeat the above procedure twice. The crude solid was triturated with petroleum ether to give the final pure ester, which was confirmed by TLC and HPLC.
    Example 9 Preparation of Di-9- (Fluorenylmethoxycarbonyl) polymyxin B [(Fmoc) 2 -PMXB]
    Polymyxin B (PMXB) is a representative substance of a group of cycle-peptide antibiotics and is effective against gram (-) bacteria. PMXB contains 5 residues of diaminobutyric acid, which acids can be modified by inserting Fmoc groups using 4- (9-fluorenylmethoxycarbonyloxy) phenyl-dimethylsulfonium methylsulfate (Fmoc-DSP). . The molar ratio of Fmoc-DSP and peptide determines the degree of modification of PMXB.
    To prepare (Fmoc) 2 -PMXB, NaHCO 3 solution (0.1 in a stirred solution of PMXB (Sigma USA; 10 mg, 7.2 μmole) and Fmoc-DSP (7.1 mg, 14.4 μmole) in H 2 O (1 mL) M, 0.15 mL) was added dropwise. The mixture was then stirred at room temperature overnight, which caused the solution to become cloudy. The precipitate obtained was centrifuged, washed twice with water and then dissolved in a small amount of DMF and precipitated with ether to give a white crude solid.
    Antibacterial Activity of Natural PMXB and (Fmoc) 2- PMXB compoundprocessConcentration at 50% inhibition of bacterial growth (μ 50 ) (IC 50 )Antibacterial activity 1) (%) Nature PMXB---0.05100 Nature PMXB3 days, 37 ° C., pH 8.5 2) 0.1100 Nature PMXB6 days, 37 ° C., pH 8.5 2) 0.2100 Nature PMXB3 days, 37 ° C., pH 7.4 3) 0.055100 Nature PMXB6 days, 37 ° C., pH 7.4 3) 0.228100 (Fmoc) 2 -PMXB---5One (Fmoc) 2 -PMXB3 days, 37 ° C., pH 8.5 2) 0.12580 (Fmoc) 2 -PMXB6 days, 37 ° C., pH 8.5 2) 0.2100 (Fmoc) 2 -PMXB3 days, 37 ° C., pH 7.4 3) 0.22725 (Fmoc) 2 -PMXB6 days, 37 ° C., pH 7.4 3) 0.3564
    (1) Numbers indicate the efficacy of PMXB used as a control in the analysis.
    (2) Incubation was performed at pH 8.5 with PMXB or (Fmoc) 2 -PMXB (100 μg / ml) in 0.1 M NaHCO 3 containing 1% DMSO.
    (3) Incubation was performed at pH 7.4 with PMXB or (Fmoc) 2 -PMXB (100 μg / ml) in 50 mM Hepes buffer (pH 7.4) containing 1% DMSO.
    100% Solution B from 70% Solution A (0.1% TFA in water) and 30% Solution B (75:25, acetonitrile: 0.1% TFA in water) over 40 minutes (flow rate, 0.8 ml / min) Linear gradient analytical HPLC (RP-18; 250 × 4 mm; Merck) showed one main product eluting at 39 minutes (holding time of PMXB under these conditions was 13.5 minutes). Crude solids were applied to preparative HPLC to give pure product. Analysis of (Fmoc) 2 -PMXB using the mass spectrum yielded the expected molecular weight (M / Z 1647 [MH] + ).
    The antimicrobial activity of (Fmoc) 2 -PMXB and native PMXB was analyzed under the following conditions: Diluted suspension of Escherichia coli (0.5 mL per glass tube) was increased at 37 ° C. for 6 hours (Fmoc) 2 -PMXB and natural PMXB. Incubated with or without the added concentration. At the indicated time, a portion was collected and analyzed for bacteriostatic activity against E. coli, and bacterial growth was assessed by measuring turbidity at 700 nm.
    As can be seen in Table 7, (Fmoc) 2 -PMXB is singer had not ceased to assume any active Possession (about 1%), pH 8.5, and the value of t 1/2 of 7.4 for about 3 days and one day, respectively as the active PMXB Decomposed
    Example 10 Preparation of Piperacillin-Fluorenylmethyl Ester (Pipepacillin-O-Fm)
    Piperacillin (4-ethyl-2,3-dioxopiperazinecarbonyl ampicillin) is a semi-synthetic antibiotic associated with penicillin with a broad spectrum and is ineffective upon oral administration.
    Piperacillin (free carboxyl) was prepared from piperacillin sodium salt (Sigma, USA) by acidic extraction with ethyl acetate. Piperacillin-OFm was always prepared according to the method for preparing Separexin-OFm ester disclosed in Example 8, by reacting 1 equivalent of carboxyl with 2 equivalents of 9-fluorenylmethanol, 4-dimethylaminopyridine and DCC, respectively. Prepared. The crude solid was recrystallized from DCM-ether, which gave a pure product which was confirmed by TLC and HPLC.
    Example 11 Preparation of Fmoc-Propranolol
    Propranolol [1- (isopropylamino) -3- (1-naphthyloxy) -2-propanol] is a representative substance of the β blocker group, and β-adrenaline used as an antihypertensive, antiarrhythmic and antianginal agent. It is a sex antagonist. Propranolol binds but does not activate β-adrenergic receptors. Competition for this position with β-adrenergic antagonists weakens hypertension symptoms. Propranolol is administered orally to patients daily. On the other hand, most of the β-adrenergic antagonists found in nature are relatively hydrophilic and are not effectively absorbed when administered orally, for example, acetylbutorol, acenolol, betaxolol, carteolol, nado Rolls and sota rolls.
    To prepare Fmoc-propranolol, triethylamine (34 mg, 0.34) in a solution of Fmoc-OSu (170 mg, 0.50 mmol) in DCM (2.5 mL) was dissolved in dichlorochloride (DCM, 2.5 mL) over 5 minutes. mmole) and (±) -propranolol hydrochloride (50 mg, 0.17 mmole) were added dropwise to the stirred solution. The reaction mixture was stirred at rt overnight, extracted with acidified water (about pH 2), water and brine and dried over anhydrous MgSO 4 . The solution was then evaporated to give a crude solid, which was triturated with hexane to give Fmoc-propranolol. The product was confirmed by TLC (1-butanol: acetic acid: water, 8: 1: 1) and HPLC to show that it is a pure compound (under the same conditions, the retention times for propranolol and Fmoc-propranolol are respectively 16 minutes and 51 minutes). Mass spectrum (FAB) showed valid M / Z: 482.2 [M + H] + .
    Β-adrenergic efficacy of Fmoc-propranolol was analyzed. The results are shown in FIG. Freshly prepared rat adipocytes were incubated with isoproterenol (final concentration 1 μg / ml, 4 μM) and propranolol (source), Fmoc-propranolol (filled source) at 37 ° C. for 2 hours, pH Incubated with Fmoc-propranolol (square) for 7 days at 8.5 and 37 ° C. The amount of glycerol released to medium was determined according to the method disclosed in Shechter, 1982. IC50 is the amount (μM) of propranolol or N-Fmoc-propranolol derivative that inhibits the maximal rate of isoproterenol-mediated glycerol release by half.
    As can be seen in FIG. 7, Fmoc-propranolol has about 7% of the efficacy of natural propranolol. Incubation of Fmoc-propranolol at pH 8.5 (37 ° C.) for 7 days results in 50-70% of the natural drug β-adrenergic efficacy. Such derivatives have significant hydrophobicity which is a feature that promotes gastrointestinal absorption.
    Reference
    Bodanszky, M. and Bednarek, M. (1982), Int. J. Peptide Protein Res. 20, 434-37.
    Burch, RM, Weitzberg, M., Blok, N., Muhlhauser, R., Martin, D., Farmer, SG, Bator, JM, Connor, JR, Ko, C., Kuhn, W., McMillan BA Maureen, R., Shearer, BG, Tiffany, C. and Wilkins, DE (1991) Proc. Natl. Acad. Sci, USA 88, 355-359.
    3. Campbell, R. K., Campbell, L. K., White, J. R. (1996) Ann. Pharmacother. 30, 1263-71.
    Gertler, A., Ashkenazi, A. and Madar, Z. (1984) Mol. Cell Endocrinol., 34, 51-57.
    5. Kaarsholm, N.C. and Ludvigsen, S. (1995) Receptor 5, 1-8.
    6. Meyerovitch, J., Farfel, Z., Sack, J. and Shechter, Y. (1987) J. Biol. Chem. 262, 6658-6662.
    7. Meyerovitch, J., Kahn, C.R. and Shechter, Y. (1990) Biochemistry 29,3654-3660.
    8.Moody, A.J., Stan, M.A., Stan, M. and Gliemann, J. (1974) Horm. Metab. Res. 6, 12-16.
    9.Pederson, R.A., Ramanadham, S., Buchan, A.M. and McNeill, J. H. (1989) Diabetes 38, 1390-1395.
    10. Rodbell, M. (1964) J. Biol. Chem. 239, 375-380.
    11. Shechter, Y. (1982) Endocrinology 110, 1579-1583.
    12. Shechter, Y. and Ron, A. (1986) J. Biol. Chem. 261, 14945-14950.
    权利要求:
    Claims (27)
    [1" claim-type="Currently amended] Functional groups that are slowly hydrolyzed to the original active drug molecule under physiological conditions and at least one of the free amino, hydroxy, mercapto and / or carboxyl groups of the original drug molecule is sensitive to weak bases and removed under weak base conditions. Prodrug or pharmaceutically suitable salt thereof, characterized in that substituted by.
    [2" claim-type="Currently amended] The prodrug or pharmaceutically suitable salt thereof of claim 1, wherein the prodrug has the formula:
    X-Y
    In the above formula,
    Y is part of the medicament with at least one functional group selected from free amino, carboxyl, hydroxyl and / or mercapto groups; And
    X is one radical selected from radicals of the formulas (i) to (iv):

    In the above formula, R 1 and R 2 are the same or different from each other, and hydrogen, alkyl, alkoxy, alkoxyalkyl, aryl, alkaryl, aralkyl, halogen, nitro, sulfo, amino, ammonium, carboxyl, PO 3 H 2 Or OPO 3 H 2 ; R 3 and R 4 are the same as or different from each other, and are each hydrogen, alkyl or aryl; And A is OCO- when the radical is bonded to the carboxyl or mercapto group of Y, or to the amino or hydroxyl group of Y.
    [3" claim-type="Currently amended] According to claim 2, wherein Y is composed of anti-diabetic, antibiotic, synthetic antibacterial, analgesic, anti-inflammatory, anti-allergic, anti-asthmatic, anti-cholesterol, β-adrenergic blocker, antihypertensive, anti-tumor and antiviral Prodrug, characterized in that the part of the medicament for human or veterinary use selected from the group.
    [4" claim-type="Currently amended] 3. The prodrug of claim 2, wherein Y is substituted with at least one radical X consisting of R 1 is hydrogen or sulfo and radical (i) wherein R 2 , R 3 and R 4 are hydrogen.
    [5" claim-type="Currently amended] 5. The prodrug of claim 4, wherein Y is a free amino and / or carboxyl group and an optical free hydroxyl group on a portion of an insulin or insulin molecule substituted by the at least one or more radicals (i). 6.
    [6" claim-type="Currently amended] 6. The insulin derivative according to claim 5, wherein the insulin is an insulin derivative characterized in that one or two or more amino groups are substituted with 9-fluorenylmethoxycarbonyl radical (i) wherein R 1 to R 4 are hydrogen and A is OCO-. Hereinafter referred to as N- (Fmoc) -insulin).
    [7" claim-type="Currently amended] 6. The insulin derivative according to claim 5, wherein the insulin is an insulin derivative wherein one or more carboxyl groups are substituted with 9-fluorenylmethyl radical (i) wherein R 1 to R 4 are hydrogen and A is a covalent bond (hereinafter, C- (Fm) -insulin).
    [8" claim-type="Currently amended] The method of claim 5, wherein the insulin is an insulin derivative, characterized in that one or more amino groups are substituted by Fmoc radicals and one or more carboxyl groups are substituted by Fm radicals (hereinafter, N- (Fmoc), C- ( Fm) -insulin).
    [9" claim-type="Currently amended] 6. The insulin derivative of claim 5, wherein the insulin is an insulin derivative wherein one or more carboxyl groups are substituted for a Fm radical and one or more hydroxyl groups are substituted for a Fmoc radical (hereinafter, C- (Fm), O -(Fmoc) -insulin).
    [10" claim-type="Currently amended] 6. The insulin derivative of claim 5, wherein the insulin is an insulin derivative wherein one or more amino and carboxyl groups are substituted for Fmoc radicals and one or more hydroxyl groups are substituted for Fm radicals (hereinafter, N, O- ( Fmoc), called C- (Fm) -insulin).
    [11" claim-type="Currently amended] 6. The method of claim 5, wherein the insulin has 1 to 3 Fmoc substituents on the free amino group at the Gly A1 , Phe B1 or Lys B29 position, wherein A and B are chains of the insulin molecule, and Gly A1 -N- (Fmoc ) -Insulin, Phe B1 -N- (Fmoc) -insulin , Lys B29 -N- (Fmoc) -insulin , Gly A1 , Phe B11 -N- (Fmoc) 2 -insulin , Gly A1 , Lys B29 -N- ( Fmoc) 2 -insulin, Phe B1 , Lys B29- N- (Fmoc) 2 -insulin and Gly A1 , Phe B1 , Lys B29- N- (Fmoc) 3 -insulin derivatives characterized in that it is selected from the group of.
    [12" claim-type="Currently amended] The method of claim 5, wherein the insulin has one to three 2-sulfo-Fmoc substituents (hereinafter referred to as Sulfmoc) in the free amino group at the Gly A1 , Phe B1 or Lys B29 position, wherein A and B are insulin molecules Is a chain of Gly A1 -N- (Sulfmoc) -insulin, Phe B1 -N- (Sulfmoc) -insulin, Lys B29 -N- (Sulfmoc) -insulin, Gly A1 , Phe B11 -N- (Sulfmoc) 2- With insulin, Gly A1 , Lys B29 -N- (Sulfmoc) 2 -insulin, Phe B1 , Lys B29 -N- (Sulfmoc) 2 -insulin and Gly A1 , Phe B1 , Lys B29 -N- (Sulfmoc) 3 -insulin Insulin derivatives, characterized in that selected from the group consisting of.
    [13" claim-type="Currently amended] 13. The insulin derivative according to any one of claims 5 to 12, wherein said insulin is a (Fmoc, Sulfomoc or Fm) -insulin derivative of natural, recombinant or mutated human, bovine or swine.
    [14" claim-type="Currently amended] Fmoc-growth hormone, characterized in that it is selected from human and bovine growth hormone.
    [15" claim-type="Currently amended] Fmoc Separexin, characterized in that it is selected from N-Fmoc-Separexin and Separexin fluorenylmethyl ester.
    [16" claim-type="Currently amended] Di- (fluorenylmethoxycarbonyl) -polymyxin B.
    [17" claim-type="Currently amended] Pyreracillin fluorenylmethyl ester.
    [18" claim-type="Currently amended] Fmoc-propranolol.
    [19" claim-type="Currently amended] A pharmaceutical composition comprising the prodrug of any one of claims 1-18 or a pharmaceutically suitable salt thereof and a pharmaceutically suitable carrier.
    [20" claim-type="Currently amended] The pharmaceutical composition of claim 19, wherein the composition comprises the N- (Fmoc) -insulin of claim 5.
    [21" claim-type="Currently amended] The pharmaceutical composition of claim 20, wherein the composition comprises natural or recombinant human N- (Fmoc) 3 -insulin and / or natural and / or recombinant human N- (Fmoc) 2 -insulin.
    [22" claim-type="Currently amended] The pharmaceutical composition according to any one of claims 19 to 21, wherein the composition is for subcutaneous infusion, transdermal or oral administration.
    [23" claim-type="Currently amended] Use of the prodrug of any one of claims 1 to 18 for the manufacture of a pharmaceutical composition.
    [24" claim-type="Currently amended] A method for treating diabetes, comprising administering to a diabetic an effective amount of at least one insulin derivative of any one of claims 5 to 13.
    [25" claim-type="Currently amended] The method of claim 24, wherein an effective amount of N- (Fmoc) 2 -insulin and N- (Fmoc) 3 -insulin is administered to the patient at 5-8 day intervals.
    [26" claim-type="Currently amended] 26. The method of claim 24 or 25, wherein the N- (Fmoc) -insulin is administered by subcutaneous infusion.
    [27" claim-type="Currently amended] 27. The method of any one of claims 24 to 26, wherein the method is administered by injecting insulin daily.
    类似技术:
    公开号 | 公开日 | 专利标题
    US9688737B2|2017-06-27|Protease stabilized acylated insulin analogues
    JP2018021081A|2018-02-08|Novel glucagon analogs
    JP6549741B2|2019-07-24|PEGylated OXM mutant
    JP2017206561A|2017-11-24|Composition for long-acting peptide analog
    US20160000927A1|2016-01-07|Reversible pegylated drugs
    JP5475836B2|2014-04-16|New insulin derivatives
    JP6182134B2|2017-08-16|Long-acting GLP-1 / glucagon receptor agonist
    US9074015B2|2015-07-07|Recombinantly expressed insulin polypeptides and uses thereof
    JP5750494B2|2015-07-22|Insulin-oligomer complex, formulation and use thereof
    CA2689909C|2016-04-05|Long-acting polymeric prodrugs of exendin
    ES2369895T3|2011-12-07|Monocatenary insulin.
    US7060675B2|2006-06-13|Methods of treating diabetes mellitus
    DE69434224T2|2005-08-25|Oral delivery system for desferrioxamine, insulin and cromolyn sodium
    TWI362392B|2012-04-21|Acylated glp-1 compounds
    JP5710253B2|2015-04-30|Fast-acting insulin analogue
    ES2232820T3|2005-06-01|Glucagona type insulinotropic peptid analogs, compositions and use procedures.
    JP5755398B2|2015-07-29|Elongated GLP-1 compound
    AU612141B2|1991-07-04|Novel insulin derivatives
    AU2008288413B2|2013-09-26|Insulin analogues with an acyl and aklylene glycol moiety
    US20150368311A1|2015-12-24|Exendin-4 Derivatives as Selective Glucagon Receptor Agonists
    US5750497A|1998-05-12|Acylated insulin
    CN100411683C|2008-08-20|Medicinal compositions containing ghrelin
    US6451970B1|2002-09-17|Peptide derivatives
    RU2498814C2|2013-11-20|Peg-modified exendin or exendin analogue and its compositions and use
    US20160368961A1|2016-12-22|Glycosylated Polypeptide and Drug Composition Containing said Polypeptide
    同族专利:
    公开号 | 公开日
    BR9711045A|1999-08-17|
    IL119029D0|1996-11-14|
    DE69734607D1|2005-12-15|
    DE69734607T2|2006-08-03|
    CN1227501A|1999-09-01|
    NO990518L|1999-04-06|
    AU3706097A|1998-02-25|
    CA2261835A1|1998-02-12|
    EP1019089B1|2005-11-09|
    HU0000809A2|2000-11-28|
    AT308998T|2005-11-15|
    WO1998005361A2|1998-02-12|
    US6504005B1|2003-01-07|
    CA2261835C|2008-07-29|
    ES2252787T3|2006-05-16|
    IL128274A|2006-08-01|
    JP2000515542A|2000-11-21|
    WO1998005361A3|1998-06-18|
    JP4416184B2|2010-02-17|
    AU725468B2|2000-10-12|
    CZ36999A3|1999-07-14|
    NO990518D0|1999-02-04|
    DK1019089T3|2006-03-13|
    IL128274D0|1999-11-30|
    NZ333845A|2000-09-29|
    EP1019089A2|2000-07-19|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    1996-08-07|Priority to IL11902996A
    1996-08-07|Priority to IL119029
    1997-08-05|Application filed by 폴리나 벤-아미;야코브 코헨, 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드
    2000-05-25|Publication of KR20000029806A
    优先权:
    申请号 | 申请日 | 专利标题
    IL11902996A|IL119029D0|1996-08-07|1996-08-07|Long-acting drugs and pharamaceutical compositions comprising them|
    IL119029|1996-08-07|
    [返回顶部]